Media Outlets Examine Barriers To TB R&D, Access To Treatment

Devex: Will new TB treatments reach those who need them most?
“Pharma giant GlaxoSmithKline is pursuing new treatments for tuberculosis but insists it will need support from governments and funding agencies if it is to get them to patients in lower-income countries, the head of its global health unit, David Barros-Aguirre, told Devex. … Barros-Aguirre said any future treatments won’t be made widely available without collaboration and sustainable funding models to translate scientific discoveries into benefits for the most vulnerable…” (Root, 4/10).

How We Get To Next/Quartz Africa: Sexism is making the global tuberculosis epidemic worse
“…The simplest TB treatment regimen has not changed for a half-century, in large part because TB is not considered a lucrative investment for pharmaceutical research. … There has been considerable progress on policies and reforms that address the intersections between gender and health, but it’s often limited to mitigating the symptoms of sexism, rather than tackling its roots. These roots, as experience with TB shows us, can influence patient outcomes, regardless of how any particular disease is distributed across the sexes…” (Akugizibwe, 4/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.